Leucovorin Calcium is an active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs. Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity.

The global Leucovorin Calcium market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Leucovorin Calcium volume and value at global level, regional level and company level. From a global perspective, this report represents overall Leucovorin Calcium market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Pfizer
Eli Lilly
Hikma Pharmaceuticals
Sagent Pharmaceuticals
Jiangsu Hengrui Medicine
...

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Injection
Tablets

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies